Pharma BD Deal Intelligence

Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program)

2015 · Co-Development · $265M · Complete

Announcement Sentiment

Strongly positive

Theravance Biopharma and Mylan partnered on development and commercialization of TD-4208 (revefenacin), a once-daily nebulized LAMA for COPD. Mylan paid $15M cash plus $30M equity investment at signing, with up to $220M in development/sales milestones. Mylan led US commercialization with Theravance co-promote rights; Mylan led ex-US (excluding China) development.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Feb 02, 2015
Closed Feb 02, 2015
Deal value $265M
Deal type Co-Development
Therapeutic area Chronic obstructive pulmonary disease (COPD)
Indications Chronic obstructive pulmonary disease (COPD)
Key assets Revefenacin (TD-4208)
Mechanism Long-acting muscarinic antagonist (LAMA), nebulized once-daily

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals